Trials / Completed
CompletedNCT00071539
Safety and Efficacy Study to Treat Recurrent Grade 4 Malignant Brain Tumors
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 56 (actual)
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Immunotoxins can locate tumor cells and kill them without harming normal cells. Immunotoxin therapy may be effective in treating malignant glioma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TP-38 | Recombinant chimeric protein |
| DRUG | TP38 | recombinant chimeric protein |
Timeline
- Start date
- 2003-10-01
- Primary completion
- 2006-01-01
- Completion
- 2006-07-01
- First posted
- 2003-10-29
- Last updated
- 2012-01-20
Source: ClinicalTrials.gov record NCT00071539. Inclusion in this directory is not an endorsement.